Provider fact sheet · dataset v2026.08.14-4 · last touched 2026-08-14
Hims: GLP-1 programs, prices, and verification status (2026)
Hims is a unverified entry in our universe. A pivot story.
Programs and pricing, in plain sentences
tirzepatide (injection) — status: unverified. Brand-forward platform; compounded availability has shifted repeatedly since 2025
Every figure above carries its status — operator claims come from the provider, reported from third parties we cite, verified only after our own checkout walk. Machine-readable version: providers.json.
Verification status and open items
Current status: unverified, last touched 2026-08-14. Open verification items: dispensing pharmacy identity, state coverage map, cancellation terms. Source on file: trytrimi.com. Corrections land within 48 hours via the public log — if your checkout contradicts this page, that report changes the dataset.
How Hims fits the market
A pivot story. After Novo Nordisk's February 2026 lawsuit and the March partnership that followed, Hims stopped advertising compounded GLP-1s and moved to brand-forward Wegovy offers. Our ~$329 compounded figure is historical and flagged as such; the page tracks the transition and what it means for existing compounded subscribers. Where it lands overall: the price ladder, the category winners, and the program finder all compute from the same dataset this page renders.
Advertising disclosure: outbound provider links may be commission-bearing; our partner relationship with NexLife is disclosed on the ownership page and never alters statuses or rankings.